Artwork

Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Behind BRK, Biochemistry and Breast Cancer: Erique Lukong

29:28
 
공유
 

Manage episode 315146454 series 2876289
Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Dr. Erique Lukong grins, pointing to two bracelets on his wrist. One inscribed with the word 'focus'; the other 'believe'.

"I'm passionate about what I do,' he said, describing his journey through medicine as a series of lucky breaks.

In his home country of Cameroon, Lukong was identified early as a promising scholar. Upon graduating from high school, he won an eight-year government scholarship to master both biochemistry and French linguistics.

"They were looking for technical and medical translators to come back to the country," said Lukong, who enroled at Keele University in the United Kingdom, earning double bachelor's degrees.

Lukong then moved to the University of Montreal for his masters-level work.

But his career path changed, after Cameroon's economic and political crisis during the early 1990s. With a young family to support, Lukong opted to stay in North America.

"I had nobody to guide me," said Lukong. "I didn't have somebody who looked like me anywhere."

Undeterred, his work on lysosomes and identifying mutations brought him to McGill, Harvard, and finally the University of Saskatchewan.

Today his lab focuses on the biochemistry of breast cancer.

"From the very first person that I saw, I was already welcome," said Lukong, who vividly remembers the contrast between his job interview in Saskatoon and Quebec. "Everybody was welcoming."

Lukong is a biochemistry professor and a member of the University of Saskatchewan's Cancer Research Cluster.

His lab aims to pinpoint what BReast tumor Kinase (BRK), non-receptor tyrosine kinase is doing in these patients' bodies. Lukong is also investigating whether its presence is what's leading them to become drug-resistant.

"The big problem we have right now is drug resistance," said Lukong.

He said nearly a third of breast cancer patients taking Tamoxifen will develop some resistance to it.

It's even tougher with Fulvestrant, a secondary treatment, one whose effect wears off in almost all patients over time.

"That's the new direction my lab is taking now," said Lukong.

Lukong also makes time to mentor his researchers, and to find out what their goals are.

For him, one of the most difficult aspects of pursuing a career in biomedical science was that no one else looked like him.

Even today, Lukong said a number of promising Black students often drift away from their studies, or give up on academia.

"All they need is that role model" said Lukong.

Last year, he became the vice-president of the Canadian Black Scientists Network, which is set to hold its first conference for Black Excellence in Science, Technology, Engineering, Mathematics and Medicine/Health next month.

The four-day "BE-STEMM 2022" virtual conference begins January 30, 2022.

"That's why I'm here. To tell them, you can do it," said Lukong.

  continue reading

79 에피소드

Artwork
icon공유
 
Manage episode 315146454 series 2876289
Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Office of the Vice-Dean Research, College of Medicine, University of Saskatchewan., University of Saskatchewan, OVDR, and College of Medicine 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Dr. Erique Lukong grins, pointing to two bracelets on his wrist. One inscribed with the word 'focus'; the other 'believe'.

"I'm passionate about what I do,' he said, describing his journey through medicine as a series of lucky breaks.

In his home country of Cameroon, Lukong was identified early as a promising scholar. Upon graduating from high school, he won an eight-year government scholarship to master both biochemistry and French linguistics.

"They were looking for technical and medical translators to come back to the country," said Lukong, who enroled at Keele University in the United Kingdom, earning double bachelor's degrees.

Lukong then moved to the University of Montreal for his masters-level work.

But his career path changed, after Cameroon's economic and political crisis during the early 1990s. With a young family to support, Lukong opted to stay in North America.

"I had nobody to guide me," said Lukong. "I didn't have somebody who looked like me anywhere."

Undeterred, his work on lysosomes and identifying mutations brought him to McGill, Harvard, and finally the University of Saskatchewan.

Today his lab focuses on the biochemistry of breast cancer.

"From the very first person that I saw, I was already welcome," said Lukong, who vividly remembers the contrast between his job interview in Saskatoon and Quebec. "Everybody was welcoming."

Lukong is a biochemistry professor and a member of the University of Saskatchewan's Cancer Research Cluster.

His lab aims to pinpoint what BReast tumor Kinase (BRK), non-receptor tyrosine kinase is doing in these patients' bodies. Lukong is also investigating whether its presence is what's leading them to become drug-resistant.

"The big problem we have right now is drug resistance," said Lukong.

He said nearly a third of breast cancer patients taking Tamoxifen will develop some resistance to it.

It's even tougher with Fulvestrant, a secondary treatment, one whose effect wears off in almost all patients over time.

"That's the new direction my lab is taking now," said Lukong.

Lukong also makes time to mentor his researchers, and to find out what their goals are.

For him, one of the most difficult aspects of pursuing a career in biomedical science was that no one else looked like him.

Even today, Lukong said a number of promising Black students often drift away from their studies, or give up on academia.

"All they need is that role model" said Lukong.

Last year, he became the vice-president of the Canadian Black Scientists Network, which is set to hold its first conference for Black Excellence in Science, Technology, Engineering, Mathematics and Medicine/Health next month.

The four-day "BE-STEMM 2022" virtual conference begins January 30, 2022.

"That's why I'm here. To tell them, you can do it," said Lukong.

  continue reading

79 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드